CAR-T cell therapy in hematological malignancies: current opportunities and challenges
X Zhang, L Zhu, H Zhang, S Chen, Y Xiao - Frontiers in immunology, 2022 - frontiersin.org
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …
treatment, and it has achieved unprecedented success in hematological malignancies …
Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion
D Gumber, LD Wang - EBioMedicine, 2022 - thelancet.com
Chimeric antigen receptor (CAR) T cell therapy has emerged as a cancer treatment with
enormous potential, demonstrating impressive antitumor activity in the treatment of …
enormous potential, demonstrating impressive antitumor activity in the treatment of …
Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
Regulatable CAR platforms could circumvent toxicities associated with CAR-T therapy, but
existing systems have shortcomings including leakiness and attenuated activity. Here, we …
existing systems have shortcomings including leakiness and attenuated activity. Here, we …
Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells
P Agarwalla, EA Ogunnaike, S Ahn, KA Froehlich… - Nature …, 2022 - nature.com
Despite their clinical success, chimeric antigen receptor (CAR)-T cell therapies for B cell
malignancies are limited by lengthy, costly and labor-intensive ex vivo manufacturing …
malignancies are limited by lengthy, costly and labor-intensive ex vivo manufacturing …
Beyond conventional immune-checkpoint inhibition—novel immunotherapies for renal cell carcinoma
The management of advanced-stage renal cell carcinoma (RCC) has been transformed by
the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not …
the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not …
The emerging landscape of immune cell therapies
Cell therapies present an entirely new paradigm in drug development. Within this class,
immune cell therapies are among the most advanced, having already demonstrated …
immune cell therapies are among the most advanced, having already demonstrated …
Reversible ON-and OFF-switch chimeric antigen receptors controlled by lenalidomide
Cell-based therapies are emerging as effective agents against cancer and other diseases.
As autonomous “living drugs,” these therapies lack precise control. Chimeric antigen …
As autonomous “living drugs,” these therapies lack precise control. Chimeric antigen …
[HTML][HTML] Game changers in science and technology-now and beyond
UAK Betz, L Arora, RA Assal, H Azevedo… - … Forecasting and Social …, 2023 - Elsevier
The recent devastating pandemic has drastically reminded humanity of the importance of
constant scientific and technological progress. A strong interdisciplinary dialogue between …
constant scientific and technological progress. A strong interdisciplinary dialogue between …
Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies
EL Siegler, SS Kenderian - Frontiers in immunology, 2020 - frontiersin.org
Chimeric antigen receptor T (CART) cell immunotherapy has been remarkably successful in
treating certain relapsed/refractory hematological cancers. However, CART cell therapy is …
treating certain relapsed/refractory hematological cancers. However, CART cell therapy is …
Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors
Chimeric antigen receptor (CAR)-T cells showed great activity in hematologic malignancies.
However, heterogeneous antigen expression in tumor cells and suboptimal CAR-T-cell …
However, heterogeneous antigen expression in tumor cells and suboptimal CAR-T-cell …